R-BAC regimen good for older mantle cell lymphoma patients

mantle cell lymphoma.jpg

At the recent ASH meeting in San Diego, researchers from Italy presented data supporting the use of a new chemotherapy regimen in patients with previously untreated mantle cell lymphoma (MCL), or in patients with relapsed or refractory mantle cell lymphoma who had previously received one line of immunochemotherapy.

The regimen, R-BAC (rituximab, bendamustine, and cytarabine) was given to MCL patients aged 65 or older over 4-6 28 day cycles. A total of 37 patients were enrolled n the phase II study, the overwhelming majority of them with advanced stage (III or IV) disease. The median age of patients was 71.

Overall response rate (ORR) was 88%, and complete response rate (CRR) was 74%. CRR was higher among the treatment naïve patients. At a median 13 month follow-up, the 1 year progression free survival (PFS) rate was 87% in the treatment naïve patients and 62 in the other arm of the trial.

Researchers concluded that the R-BAC regimen not only has potential in treating patients over the age of 65 with mantle cell lymphoma, it is also well-tolerated.


LymphomaInfo Social